News & Analysis as of

FDA Approval Legislative Agendas

Bradley Arant Boult Cummings LLP

FDA Chief Says CBD Is Not NBD, Urges Congressional Action

Supporters of hemp-derived cannabidiol (CBD) who hoped the Food and Drug Administration would adopt a more progressive view of CBD were disappointed when FDA Chief Robert Califf recently testified that FDA does not consider...more

Manatt, Phelps & Phillips, LLP

[Webinar] Navigating the Mainstreaming of Psychedelic Drugs in the United States - October 3rd, 1:00 pm - 2:00 pm ET

In recent years, an unprecedented level of interest in the promise of psychedelics has taken hold. In the United States, many types of psychedelics are being investigated for use in treating an array of mental health...more

Manatt, Phelps & Phillips, LLP

FDA Issues New Draft Guidance on Clinical Testing of Psychedelic Drugs

On June 23, 2023, FDA issued a first-of-its-kind draft guidance for sponsors of studies of psychedelic drugs. The guidance arrived just as the Psychedelic Science 2023 conference in Denver was wrapping up. Touted as the...more

Hogan Lovells

Coronavirus: The Hill and the Headlines, June 2021 - Final Issue

Hogan Lovells on

In Washington: Centers for Disease Control and Prevention (CDC) Director Rochelle Walensky urged parents to vaccinate adolescents and teenagers against the coronavirus Friday, adding that COVID-19 can be severe for this age...more

Hogan Lovells

Coronavirus: The Hill and the Headlines, February 2021 # 19

Hogan Lovells on

In Washington: The House of Representatives was set to pass its $1.9 trillion pandemic relief package (H.R. 1319), late Friday night over solid Republican opposition. The passage is a key step toward giving President Joe...more

Hogan Lovells

Coronavirus: The Hill and the Headlines, February 2021 # 8

Hogan Lovells on

In Washington: The Senate resumed former President Trump’s impeachment trial Wednesday. House impeachment managers presented a step-by-step timeline of the January 6 assault on the Capitol aided by new evidence. Senators saw...more

Hogan Lovells

Coronavirus: The Hill and the Headlines, December 2020 # 14

Hogan Lovells on

In Washington: With only hours to spare, House and Senate lawmakers were forced to pass a last-minute short-term extension of government funding (H.J. Res. 107) to stave off a government shutdown while congressional...more

Hogan Lovells

Coronavirus: The Hill and the Headlines, December 2020 # 13

Hogan Lovells on

In Washington: Top Senate Republicans indicated on Thursday that Congress is increasingly likely to need a brief stopgap government funding bill lasting several days to clinch a spending and coronavirus relief deal. Friday...more

Hogan Lovells

Coronavirus: The Hill and the Headlines, December 2020 # 12

Hogan Lovells on

In Washington: The “four corners”— House Speaker Nancy Pelosi (D-CA), House Minority Leader Kevin McCarthy (R-CA), Senate Minority Leader Chuck Schumer (D-NY), Senate Majority Leader Mitch McConnell (R-KY)—are reportedly...more

Hogan Lovells

Coronavirus: The Hill and the Headlines, December 2020 # 9

Hogan Lovells on

In Washington: The Senate passed a one-week stopgap bill on Friday, hours ahead of a government shutdown deadline. The bill passed on a voice vote and moved the funding deadline to December 18. The continuing resolution...more

Hogan Lovells

Coronavirus: The Hill and the Headlines, December 2020 # 8

Hogan Lovells on

In Washington: The Food and Drug Administration’s (FDA) vaccine advisory panel voted to recommend that the FDA authorize the Pfizer-BioNTech vaccine for emergency use. A Centers for Disease Control and Prevention (CDC)...more

Hogan Lovells

Coronavirus: The Hill and the Headlines, December 2020 # 2

Hogan Lovells on

In Washington: Congress continues to debate a new coronavirus relief package, possibly as part of a government spending bill due December 11. Here are the latest developments...more

Hogan Lovells

Coronavirus: The Hill and the Headlines, November 2020 # 14

Hogan Lovells on

In Washington: Two Treasury Department moves in recent days are generating controversy among lawmakers and policymakers: Treasury Secretary Steven Mnuchin announced Thursday that he will not extend the Federal...more

Hogan Lovells

Coronavirus: The Hill and the Headlines, November 2020 # 12

Hogan Lovells on

In Washington: Wednesday, the House held its leadership elections reelecting Rep. Nancy Pelosi (D-CA) as Speaker of the House by her caucus. Other top Democratic leaders, Majority Leader Steny Hoyer (D-MD) and Majority...more

Hogan Lovells

Coronavirus: The Hill and the Headlines, November 2020 # 9

Hogan Lovells on

In Washington: Two public health experts on President-elect Biden’s COVID-19 task force rejected the idea of broad “lockdowns” like those seen in the spring designed to slow skyrocketing case numbers. Celine Gounder told...more

Hogan Lovells

Coronavirus: The Hill and the Headlines, October 2020 # 4

Hogan Lovells on

In Washington: President Trump left Walter Reed Medical Center Monday evening despite his personal doctor, Sean Conley, saying he “may not be entirely out of the woods yet.” In a memo on Tuesday, his doctor said the...more

Hogan Lovells

Coronavirus: The Hill and the Headlines – COVID-19 D.C. Update – August 2020 # 14

Hogan Lovells on

In Washington - Senator Bill Cassidy (R-LA) has tested positive for coronavirus. Cassidy took a test on Thursday evening after being informed that he had been exposed to an individual with COVID-19. He is quarantining for...more

Seyfarth Shaw LLP

The Week in Weed: June 2020

Seyfarth Shaw LLP on

Louisiana is expanding medical marijuana, and the United Nations may reschedule cannabis.  Meanwhile, PetSmart faces a lawsuit over pet CBD.  MedMen has campaign finance problems, and the 9th Circuit looks at taxes....more

Hogan Lovells

Coronavirus: The Hill and the Headlines – COVID-19 D.C. Update – May 2020 #6

Hogan Lovells on

In Washington: The House schedule is still up in the air and there is no new information on when Democrats will release their draft of the new coronavirus stimulus legislation....more

Seyfarth Shaw LLP

FDA and NCI to Review COVID-19 Antibody Tests Marketed Under FDA Guidance Permitting Sale Without FDA Authorization

Seyfarth Shaw LLP on

In mid-March, the US Food and Drug Administration announced via press release an “unprecedented policy” to increase testing capacity for COVID-19 in the United States. As part of its Policy for Diagnostic Tests for...more

Hogan Lovells

Senate bill proposes laboratory developed tests to be regulated under CLIA process

Hogan Lovells on

U.S. Senator Rand Paul introduced legislation that would place laboratory developed testing procedures within the Clinical Laboratory Improvement Amendments (CLIA) process and assess the availability and utilization of...more

McDonnell Boehnen Hulbert & Berghoff LLP

FDA Continues to Approve Biosimilars

The prevailing attitude in many quarters is that the Biologics Price Competition and Innovation Act (BPCIA) has not facilitated approval of drugs biosimilar to reference biologic drug products with sufficient alacrity and has...more

Wilson Sonsini Goodrich & Rosati

Sitting Here on Capitol Hill: Congressional Developments on Life Science and Consumer Product Issues

Letters and Statements - Gene Therapy: Democratic Senators Urge the FDA to Hold Company Accountable for Falsifying Data - On August 9, 2019, a group of Democratic senators, including two presidential candidates, sent...more

Foley & Lardner LLP

Health Care Policy Newsletter - July 2018

Foley & Lardner LLP on

Foley & Lardner LLP’s (“Foley”) Bipartisan Public Policy Team is pleased to share our “Public Policy Weekly* Health Care Newsletter” in which we compile the latest Health care policy news and legislation. *Please note that we...more

Hogan Lovells

A new right for American patients: The Right to Try

Hogan Lovells on

On May 22, 2018, the U.S. House of Representatives passed Senate Bill 204, commonly known as the “Right to Try Act of 2017” by a vote of 250-169. The bill gives certain patients with life-threatening conditions the right to...more

28 Results
 / 
View per page
Page: of 2

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide